Novavax (NVAX) is poised for significant growth with its partnership with Sanofi for COVID-19 vaccine co-commercialization. The $1.2 billion deal marks a major milestone for Novavax, fueling investor excitement and boosting stock prices. With this partnership, Novavax is expected to explode, making it a prime candidate for investors seeking high-potential growth stocks.